Neurogene Research and Development Expenses 2013-2024 | NGNE

Neurogene research and development expenses from 2013 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Neurogene Research and Development Expenses 2013-2024 | NGNE

Neurogene research and development expenses from 2013 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$174.8B
Vertex Pharmaceuticals (VRTX)$133.1B
Gilead Sciences (GILD)$120.2B
Bristol Myers Squibb (BMY)$109.8B
Regeneron Pharmaceuticals (REGN)$91B
CSL (CSLLY)$90.5B
GSK (GSK)$75.2B
Alnylam Pharmaceuticals (ALNY)$35.8B
Argenex SE (ARGX)$35.6B
BioNTech SE (BNTX)$26.3B
Biogen (BIIB)$25.2B
Illumina (ILMN)$24B
BeiGene (BGNE)$20B
Moderna (MRNA)$18B
Incyte (INCY)$16.1B
Genmab (GMAB)$15.3B
Vaxcyte (PCVX)$13.3B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$12.8B
Bio-Techne Corp (TECH)$12.1B
Sarepta Therapeutics (SRPT)$11.6B
Exelixis (EXEL)$10.4B
Revolution Medicines (RVMD)$10.2B
QIAGEN (QGEN)$10B
Intra-Cellular Therapies (ITCI)$9.7B
Exact Sciences (EXAS)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.8B
Repligen (RGEN)$7.9B
Halozyme Therapeutics (HALO)$7.8B